↓ Skip to main content

Dove Medical Press

Article Metrics

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin

Overview of attention for article published in Drug Design, Development and Therapy, September 2013
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
40 Dimensions

Readers on

mendeley
104 Mendeley
Title
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
Published in
Drug Design, Development and Therapy, September 2013
DOI 10.2147/dddt.s37647
Pubmed ID
Authors

Dario Giugliano, Liberata Sportiello, Annalisa Capuano, Mariaida Maiorino, Francesco Rossi, Katherine Esposito

Abstract

Type 2 diabetes mellitus is a complex and progressive disease that is showing an apparently unstoppable increase worldwide. Although there is general agreement on the first-line use of metformin in most patients with type 2 diabetes, the ideal drug sequence after metformin failure is an area of increasing uncertainty. New treatment strategies target pancreatic islet dysfunction, in particular gut-derived incretin hormones. Inhibition of the enzyme dipeptidyl peptidase-4 (DPP-4) slows degradation of endogenous glucagon-like peptide-1 (GLP-1) and thereby enhances and prolongs the action of the endogenous incretin hormones. The five available DPP-4 inhibitors, also known as 'gliptins' (sitagliptin, vildagliptin, saxagliptin, linagliptin, alogliptin), are small molecules used orally with similar overall clinical efficacy and safety profiles in patients with type 2 diabetes. The main differences between the five gliptins on the market include: potency, target selectivity, oral bioavailability, long or short half-life, high or low binding to plasma proteins, metabolism, presence of active or inactive metabolites, excretion routes, dosage adjustment for renal and liver insufficiency, and potential drug-drug interactions. On average, treatment with gliptins is expected to produce a mean glycated hemoglobin (HbA1c) decrease of 0.5%-0.8%, with about 40% of diabetic subjects at target for the HbA1c goal <7%. There are very few studies comparing DPP-4 inhibitors. Alogliptin as monotherapy or added to metformin, pioglitazone, glibenclamide, voglibose, or insulin therapy significantly improves glycemic control compared with placebo in adult or elderly patients with inadequately controlled type 2 diabetes. In the EXAMINE trial, alogliptin is being compared with placebo on cardiovascular outcomes in approximately 5,400 patients with type 2 diabetes. In clinical studies, DPP-4 inhibitors were generally safe and well tolerated. However, there are limited data on their tolerability, due to their relatively recent marketing approval. Alogliptin will be used most when avoidance of hypoglycemic events is paramount, such as in patients with congestive heart failure, renal failure, and liver disease, and in the elderly.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 104 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Ireland 1 <1%
Brazil 1 <1%
Unknown 102 98%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 19 18%
Researcher 17 16%
Student > Master 17 16%
Student > Ph. D. Student 12 12%
Other 9 9%
Other 21 20%
Unknown 9 9%
Readers by discipline Count As %
Medicine and Dentistry 46 44%
Pharmacology, Toxicology and Pharmaceutical Science 16 15%
Agricultural and Biological Sciences 13 13%
Biochemistry, Genetics and Molecular Biology 7 7%
Chemistry 6 6%
Other 4 4%
Unknown 12 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 November 2013.
All research outputs
#2,303,066
of 4,507,509 outputs
Outputs from Drug Design, Development and Therapy
#202
of 566 outputs
Outputs of similar age
#50,030
of 100,620 outputs
Outputs of similar age from Drug Design, Development and Therapy
#10
of 30 outputs
Altmetric has tracked 4,507,509 research outputs across all sources so far. This one is in the 35th percentile – i.e., 35% of other outputs scored the same or lower than it.
So far Altmetric has tracked 566 research outputs from this source. They receive a mean Attention Score of 1.9. This one is in the 49th percentile – i.e., 49% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 100,620 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 35th percentile – i.e., 35% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 30 others from the same source and published within six weeks on either side of this one. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.